Home4DX • ASX
4DMedical Ltd
$0.60
Apr 18, 7:00:00 PM GMT+10 · AUD · ASX · Disclaimer
StockAU listed security
Previous close
$0.57
Day range
$0.57 - $0.61
Year range
$0.45 - $1.27
Market cap
234.82M AUD
Avg Volume
733.73K
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
Financials
Income Statement
Revenue
Net income
(AUD)Dec 2023Y/Y change
Revenue
396.25K63.11%
Operating expense
12.15M7.01%
Net income
-7.80M3.85%
Net profit margin
-1.97K41.05%
Earnings per share
EBITDA
-11.28M-7.20%
Effective tax rate
-0.29%
Total assets
Total liabilities
(AUD)Dec 2023Y/Y change
Cash and short-term investments
47.88M4.67%
Total assets
143.73M119.44%
Total liabilities
52.60M138.47%
Total equity
91.13M
Shares outstanding
390.88M
Price to book
2.48
Return on assets
-20.49%
Return on capital
-30.77%
Net change in cash
(AUD)Dec 2023Y/Y change
Net income
-7.80M3.85%
Cash from operations
-7.37M-193.62%
Cash from investing
-19.68M-3,634.63%
Cash from financing
16.20M4,504.90%
Net change in cash
-10.85M-303.99%
Free cash flow
-6.46M4.65%
About
4DMedical is a medical technology company, based in Australia and the United States. 4DMedical created X-ray Velocimetry Lung Ventilation Analysis Software based on the company's proprietary XV Technology. XV Technology uses patented algorithms adapted from advanced aerodynamics research to process and enhance X-ray and Computed Tomography images. Airflow is measured throughout all regions of the lung, across all phases of the breath—providing clinicians with quantitative lung ventilation data in a report. 4DMedical has commercialized its XV Technology via a Software as a Service model, where patients are scanned using existing imaging equipment and analyzed by 4DMedical remotely. Airflow is measured throughout all regions of the lung, across all phases of the breath, delivering the capability to quantify regional lung function throughout the respiratory cycle, at every location within the lung. The lung function data is provided to clinicians and patients in a report that includes color-coded lung images. This approach enables the detection of subtle functional losses before lung structure is irreversibly effected by the disease. Wikipedia
Founded
2013
Employees
131
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu